GRP logo
Quality Improvement of Cost-Effectiveness Research

The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report

The citation for this report is:
McGhan WF, Al M, Doshi JA, et al. The ISPOR Good Practices for Quality Improvement of Cost-Effectiveness Research Task Force Report. Value Health 2009;12.

Task Force Chair
William McGhan, PharmD, PhD, Professor of Pharmacy and Health Policy, University of the Sciences, Philadelphia, PA, USA

Leadership Group
Maiwenn Al, PhD, Senior Research Fellow, institute for Medical Technology Assessment (iMTA), Erasmus MC, Rotterdam, Netherlands
Jalpa Doshi, PhD, Professor of Medicine, University of Pennsylvania, Philadelphia, PA, USA
Isao Kamae, MD, DrPH, Professor of Pharmacoeconomics, Graduate School of Health Management, Keio University, Fujisawa, Japan
Steven E. Marx, PharmD, MS, Associate Director, Global Pharmaceutical Research & Development, Abbott Laboratories, Chicago, IL, USA
Donna Rindress, PhD, President & Managing Director, BioMedCom Consultants, Inc., Montreal, Quebec, Canada

Background
While the average health care researcher or practitioner may be able to follow major health care economic indicators and the release of major health care economic studies, a process to track overall quality of health care economic studies and their use in making health care policies is needed. Reviews and periodic quality reports advance international health care efficiency and quality and become a mainstay of our global effort to improve the economics and quality of life in all health care sectors.

Methods and statistics used in health care economic studies need to be critiqued periodically to improve the quality and usefulness for these studies and guidelines. It is also important to monitor the quality of health care economic study guidelines being used by journals, organizations and governments around the world for assessing new therapies and allocation of resources.

For more information, see: QUALITY IMPROVEMENT OF HEALTH CARE ECONOMIC EVALUATION RESEARCH AND USE IN HEALTH CARE POLICY

The mission of the ISPOR Quality Improvement of Cost Effectiveness Research (QICER) Task Force (through surveys, white papers, and sessions at ISPOR meetings) is to report and facilitate the improvement of health care economic evaluation research and its use in making health care policy.

The specific tasks are to:

  1. Develop periodic reports on the state and quality of health care economic evaluations and use of these studies in making health care policy
  2. Develop recognition of good health care economic evaluation research
  3. Develop a repository of ‘reference cases’ for health care economic evaluation research
  4. Develop a report card on the quality of journal guidelines on health care economic evaluations as well as government guidelines on health care economic evaluation information

*Health care economic evaluation research includes: budget impact analysis, cost-benefit analysis, cost-effectiveness analysis, cost-efficiency analysis, cost-consequence, cost-minimization analysis, cost-utility analysis, cost of illness, and cost of treatment studies

Draft Final Report
May 2009: The revised draft final report was presented for additional member comment during ISPOR’s 14th Annual International Meeting in Orlando, Florida; the presentation can be viewed at: www.ispor.org/TaskForces/documents/ISPOR14thAnnualMeetingQICERForum.pdf

May 2008: The QICER Task Force presented their draft report including responses to member comments during an open forum at ISPOR’s 13th Annual International Meeting in Toronto, Ontario.  The task force’s forum presentation can be viewed at: www.ispor.org/workpaper/healthscience/QICERforumslidesMay12008.pdf


ISPOR Good Practices For Outcomes Research Index